What Is Cerebrolysin? Benefits, Research & Safety
A multi-peptide neuroprotective preparation derived from porcine brain tissue, approved in some countries for stroke recovery and neurodegenerative conditions.
UK summary: Not a licensed UK medicine. A multi-peptide preparation from porcine brain tissue, licensed in several European and Asian countries for stroke recovery, dementia, and TBI. Substantial regional clinical literature, much from Russian / Chinese groups; not on UK NHS pathways.
Quick Facts
Overview
Cerebrolysin — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. A multi-peptide preparation from porcine brain tissue, licensed in several European and Asian countries for stroke recovery, dementia, and TBI. Substantial regional clinical literature, much from Russian / Chinese groups; not on UK NHS pathways.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not approved by the MHRA. Not available through standard UK prescribing.
- EU: Approved in several EU member states (Austria, Germany, and others) for neurological indications.
- Notes: Approved in over 40 countries worldwide. Not approved by the FDA or MHRA. Available on prescription in approved countries.
05Approved medical uses
- Stroke recovery (licensed in several European, Asian, and Latin American countries; NOT MHRA-licensed in the UK).
- Alzheimer's disease and vascular dementia (licensed in some jurisdictions; NOT in the UK).
- Traumatic brain injury rehabilitation (licensed in some jurisdictions; NOT in the UK).
06Unapproved / promotional claims
- Reverses Alzheimer's disease.
- Cures stroke damage if started early.
- Boosts cognition in healthy adults for exam prep or high-stakes work.
- Safe to self-administer at home as IV or IM infusion.
07Common internet claims
- Marketed by private 'neuroregeneration' clinics for off-label cognitive enhancement.
- Sold by online retailers as research-only injectable.
- Promoted in nootropic stacks alongside Semax and Selank.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Recovers function after stroke” | C | Yes | Moderate | Licensed in many jurisdictions with positive trial data; UK guidelines do not include Cerebrolysin. |
| “Treats Alzheimer's” | C | Limited | Moderate | Some trials report cognitive benefits; not a UK-licensed Alzheimer's treatment. |
| “Boosts cognition in healthy adults” | E | No | High | No evidence for healthy-adult cognitive enhancement. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Injection-site reactions; fever, sweating, dizziness reported.
- Theoretical risk from porcine-brain-derived preparation (BSE-class concerns historically reviewed).
- Hypersensitivity reactions possible.
- Sterility and prion-screening of grey-market vials unverified.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
Not approved by the MHRA. Not available through standard UK prescribing.
Read the full UK legal guide → Are peptides legal in the UK?
14EU legal position
Approved in several EU member states (Austria, Germany, and others) for neurological indications.
15What this page cannot tell you
- Whether a UK-purchased vial is genuine Cerebrolysin from the licensed manufacturer.
- Whether IV/IM technique used outside a clinic is sterile.
- What outcome benefit (if any) applies to your specific neurological condition.
- Whether the Russian/Chinese trial evidence base would meet UK NICE quality thresholds.
16Last reviewed
17Citation quality score
18Research gaps
- No UK NICE technology appraisal supports Cerebrolysin for any indication.
- Western Phase 3 trial replication of stroke / dementia benefits limited.
- Healthy-adult cognitive-outcome data absent.
- Long-term safety in non-licensed jurisdictions unstudied.
19Safer alternatives / established care pathways
- NHS stroke pathway with evidence-based rehabilitation (physio, OT, SLT).
- NHS memory clinic for cognitive concerns and licensed Alzheimer's medications.
- NHS TBI rehabilitation pathway for traumatic brain injury.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Cerebrolysin a licensed UK medicine?
- What UK-approved treatments exist for the neurological condition I'm asking about?
- Is there an NHS specialist pathway for my situation?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Neuroprotection against excitotoxicity, oxidative stress, and apoptosis
- 2Enhancement of neuroplasticity and synaptic function
- 3Support for functional recovery after ischaemic stroke
- 4Potential cognitive improvement in Alzheimer's disease
- 5Promotion of neurogenesis from neural stem cells
- 6Improved outcomes in traumatic brain injury models
Claim vs Evidence
How popular claims about Cerebrolysin stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Recovers function after stroke” | C | Yes | Moderate | Licensed in many jurisdictions with positive trial data; UK guidelines do not include Cerebrolysin. |
| “Treats Alzheimer's” | C | Limited | Moderate | Some trials report cognitive benefits; not a UK-licensed Alzheimer's treatment. |
| “Boosts cognition in healthy adults” | E | No | High | No evidence for healthy-adult cognitive enhancement. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Clinical protocols use 10-30 mL IV daily for acute neurological conditions; 5-10 mL for chronic conditions |
| Frequency | Daily IV infusion for 10-21 day treatment cycles |
| Duration | Typical cycles of 10-21 days, repeated as clinically indicated |
| Notes | Administered by intravenous infusion in clinical settings. Not suitable for self-administration. Dosing determined by treating physician based on indication and severity. |
Administration Routes
Routes studied in research settings (educational only):
- Intravenous infusion
- Intramuscular injection (lower doses)
| Half-Life | Stability |
|---|---|
| Complex pharmacokinetics due to multi-peptide composition; clinical effects observed during and after treatment cycles | Supplied as a ready-to-use aqueous solution. Store at room temperature protected from light. |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Dizziness
- Headache
- Injection site reactions
- Agitation (rare)
- Mild gastrointestinal symptoms
Rare Risks & Concerns
- Allergic reactions
- Seizures in predisposed individuals (rare)
Contraindications
- Epilepsy
- Severe renal impairment
- Known hypersensitivity to porcine-derived products
- Pregnancy and breastfeeding
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not approved by the MHRA. Not available through standard UK prescribing.
🇪🇺 European Union
Approved in several EU member states (Austria, Germany, and others) for neurological indications.
Clinical Studies Summary
Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.
Cerebrolysin shows promise as a useful neuroprotective treatment in stroke care by dramatically improving functional recovery, reducing symptomatic intracranial bleeding, and lowering mortality in acute ischemic stroke patients when used in conjunction with mechanical thrombectomy.
Therapeutic strategies in vascular cognitive impairment: A systematic review and meta-analysis.
One-hundred seventy-three trials were extracted (22,347 participants, four VCI categories, 91 interventions, 145 outcomes). Ginkgo biloba extracts showed large to moderate improvements in cognition (Cohen's d: 0.83, 95% CI: 0.00 to 1.67) and small to moderate improvements in functional outcomes (Cohen's d: 0.50, 95% CI: 0.25 to 0.75).
The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review.
Our study demonstrated that AChE inhibitors, Ginkgo biloba, and cerebrolysin are the optimum cognitive and activities of daily living medication for patients with AD.
Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series.
A total 185 patients underwent meta-analysis (mean admission GCS = 10.3, mean age = 45.3, and mean Baseline Prognostic Risk Score = 2.8).
Cerebrolysin for acute ischaemic stroke.
Moderate-quality evidence indicates that Cerebrolysin probably has little or no beneficial effect on preventing all-cause death in acute ischaemic stroke, or on the total number of people with serious adverse events. Moderate-quality evidence also indicates a potential increase in non-fatal serious adverse events with Cerebrolysin use.
Cerebrolysin for vascular dementia.
Courses of intravenous Cerebrolysin improved cognition and general function in people living with vascular dementia, with no suggestion of adverse effects. However, these data are not definitive. Our analyses were limited by heterogeneity, and the included papers had high risk of bias. If there are benefits of Cerebrolysin, the effects may be too small to be clinically meaningful.
Registered Trials & Regulatory Status
16 of 19 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial
Status: Not Yet Recruiting · 30 participants · Cardinal Stefan Wyszynski University
Conditions: Intracerebral Hemorrhage, Hemorrhagic Stroke, Intracerebral, Hemorrhagic Stroke
Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study
Status: Recruiting · 30 participants · University Medical Centre Ljubljana
Conditions: Ischemic Stroke, Acute, Rehabilitation Outcome, Cerebrolysin
Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, Single Center Study
Status: Recruiting · 40 participants · Yonsei University
Conditions: Stroke
Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion
Status: Not Yet Recruiting · 20 participants · University Hospital Sestre Milosrdnice
Conditions: Basilar Artery Occlusion, Posterior Circulation Brain Infarction
Exploring Cerebrolysin in Late Thrombectomy for Stroke: Blood-brain Barrier Biomarkers and Imaging Insights
Status: Not Yet Recruiting · 100 participants · Chang Gung Memorial Hospital
Conditions: Acute Ischemic Stroke
Cerebrolysin in Critically Ill Patients With Delirium
Status: Enrolling By Invitation · 500 participants · Medical University of Lublin
Conditions: Cognitive Impairment
CERebrolysin In CADASIL
Status: Active Not Recruiting · 30 participants · Ever Neuro Pharma GmbH
Conditions: Cadasil
A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Stroke Patients Undergoing EndoVascular Treatment (EVT)
Status: Unknown · 30 participants · Shaare Zedek Medical Center
Conditions: Acute Ischemic Stroke
Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU
Status: Completed · 150 participants · Ain Shams University
Conditions: Traumatic Brain Injury
Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy
Status: Recruiting · 90 participants · October 6 University
Conditions: Bell Palsy
Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness
Status: Recruiting · 12 participants · Konkuk University Medical Center
Conditions: Disorder of Consciousness, Hemorrhagic Stroke
Cerebrolysin in Prevention of Postoperative Delirium in Cardiac Surgery
Status: Unknown · 100 participants · Medical University of Lublin
Conditions: Neurocognitive Disorders, Surgery-Complications, Critical Illness
Adverse event reports (FDA FAERS)
Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Cerebrolysin?
Source research-grade Cerebrolysin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Cerebrolysin
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Cerebrolysin a licensed UK medicine?
- What UK-approved treatments exist for the neurological condition I'm asking about?
- Is there an NHS specialist pathway for my situation?
UK regulatory & safety context
Related Research Guides
Related Peptides
Selank
A synthetic peptide based on tuftsin, developed in Russia for anxiolytic and nootropic properties, approved there for anxiety and neurasthenia.
Learn moreSemax
A synthetic peptide based on ACTH, developed in Russia as a nootropic and neuroprotectant, approved there for cognitive disorders and stroke.
Learn moreDSIP
A neuropeptide originally isolated for its sleep-inducing properties, now researched for stress protection, pain modulation, and metabolic effects.
Learn moreBDNF
A critical growth factor for brain health, neuroplasticity, and neuronal survival, with implications for depression, memory, and neurodegenerative diseases.
Learn more